Enwave Corp V.ENW

NEWS

[goldmember316]

Collaborative Research with Dr. Helen Burt Announced 2/8/05 VANCOUVER, Feb 08, 2005 (Canada NewsWire via COMTEX) -- EnWave Corporation ("EnWave") is pleased to announce a new collaborative research relationship with Dr. Helen Burt, Angiotech Professor of Drug Delivery in the Faculty of Pharmaceutical Sciences at The University of British Columbia. In collaboration with Dr. Burt, EnWave will design and build a new microwave-vacuum instrument specifically for processing of porous pharmaceutical and medical materials using the radiant energy and vacuum (REV) techniques developed in Dr. Durance's laboratory and described in EnWave's press releases of August 4, 2004 and December 3, 2004. The REV equipment will be funded equally by the two parties and installed on the UBC campus. "My interest in REV techniques stems from my involvement in research to develop biomaterials for bone regeneration." said Dr. Burt. "I am excited about the potential of EnWave's technology to form porous, resorbable scaffold material that, in combination with stem cell therapy and local drug delivery systems, may contribute to improving the success of revision hip replacement therapies. If successful, the same techniques are likely to be applicable to other situations requiring bone augmentation or regeneration." "We are thrilled to have this opportunity to work with Dr. Burt on these exciting new applications in the medical materials field", said Dr. Tim Durance, President of EnWave. "At the same time we expect to see synergies between the proposed research into REV techniques for tissue scaffold fabrication and our own ongoing development of REV for manufacture of microbicides." EnWave is a research and development company developing commercial applications of vacuum microwave ("VM") technology using specially designed VM processing equipment. EnWave's mission is to lead the development of VM processing systems for industrial applications in the food, feed, pharmaceutical, nutraceutical and chemical industries. Applications of the technology enable manufacturers to produce innovative, high quality products that cannot be produced using current techniques. Many of the processes producing these products have been granted patents, recognizing their innovative nature. This press release was prepared on behalf of the Board of Directors, which accepts full responsibility for its content. ON BEHALF OF THE BOARD (Signed): "Tim Durance" ----------------------------------------- Dr. Tim Durance President, C.E.O. and Corporate Secretary The TSX Venture Exchange has neither approved nor disapproved the information contained herein. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "US Securities Act") or any state securities laws and may not be offered or sold within the United States or to US Persons unless registered under the US Securities Act and applicable state securities laws or an exemption from such registration is available. VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: https://www.newswire.ca/en/releases/orgDisplay.cgi?okey=46291 For further information: Dr. Tim Durance, President [phone], fax [phone] News release via Canada NewsWire, Vancouver 604-669-7764 Copyright (C) 2005 CNW, All rights